Brokerages expect Translate Bio Inc (NASDAQ:TBIO) to report ($0.45) earnings per share for the current quarter, according to Zacks Investment Research. Three analysts have issued estimates for Translate Bio’s earnings, with the highest EPS estimate coming in at ($0.34) and the lowest estimate coming in at ($0.54). Translate Bio posted earnings per share of ($0.97) in the same quarter last year, which indicates a positive year-over-year growth rate of 53.6%. The company is expected to issue its next earnings report on Thursday, November 14th.
On average, analysts expect that Translate Bio will report full year earnings of ($2.13) per share for the current fiscal year, with EPS estimates ranging from ($2.42) to ($1.86). For the next fiscal year, analysts forecast that the business will post earnings of ($1.79) per share, with EPS estimates ranging from ($1.96) to ($1.54). Zacks’ earnings per share calculations are a mean average based on a survey of analysts that cover Translate Bio.
Translate Bio (NASDAQ:TBIO) last announced its earnings results on Wednesday, July 31st. The company reported ($0.57) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.48) by ($0.09). Translate Bio had a negative net margin of 2,696.98% and a negative return on equity of 84.05%. The business had revenue of $1.17 million during the quarter, compared to analyst estimates of $1.73 million.
A number of institutional investors have recently bought and sold shares of TBIO. Rhumbline Advisers purchased a new stake in shares of Translate Bio during the fourth quarter worth about $77,000. BlackRock Inc. grew its holdings in shares of Translate Bio by 130.2% during the fourth quarter. BlackRock Inc. now owns 982,405 shares of the company’s stock worth $7,367,000 after buying an additional 555,635 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Translate Bio by 101.4% in the fourth quarter. Bank of New York Mellon Corp now owns 27,968 shares of the company’s stock worth $210,000 after acquiring an additional 14,081 shares during the last quarter. Northern Trust Corp boosted its position in shares of Translate Bio by 12.4% in the fourth quarter. Northern Trust Corp now owns 111,339 shares of the company’s stock worth $835,000 after acquiring an additional 12,242 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Translate Bio by 139.0% in the fourth quarter. Geode Capital Management LLC now owns 117,432 shares of the company’s stock worth $880,000 after acquiring an additional 68,300 shares during the last quarter. Institutional investors and hedge funds own 57.90% of the company’s stock.
Shares of NASDAQ:TBIO traded up $0.28 during midday trading on Friday, reaching $8.31. The company’s stock had a trading volume of 430,466 shares, compared to its average volume of 165,651. Translate Bio has a fifty-two week low of $4.81 and a fifty-two week high of $14.34. The company has a debt-to-equity ratio of 1.34, a quick ratio of 7.69 and a current ratio of 7.69. The stock’s fifty day simple moving average is $10.50.
Translate Bio Company Profile
Translate Bio, Inc, a clinical-stage messenger RNA (mRNA) therapeutics company, develops medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, which is in Phase I/II clinical trial for the treatment of cystic fibrosis; and MRT5201 to treat ornithine transcarbamylase deficiency.
Further Reading: Cryptocurrencies
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Translate Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Translate Bio and related companies with MarketBeat.com's FREE daily email newsletter.